http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Interactive Flocking Simulator based on Deterministic Kinetic Model
Ken Sugawara,Kanako Hata 제어로봇시스템학회 2009 제어로봇시스템학회 국제학술대회 논문집 Vol.2009 No.8
We propose a new drawing tool based on the dynamics of collective behaviors reported in our previous work. Dynamics of collective motion is described by fundamental kinetics of particles and the dynamics of the heading which each element has as a degree of freedom. We firstly explain the model in detail and show various types of behavior such as marching, oscillatory, wandering and swarming emerges by computer simulation. Next, we show the drawing tool based on the dynamics. Users can draw any object by electric pen, and the drawn objects are characterized by their shape, and show collective motions based on the characteristics. Performance of the tool is evaluated by two-dimensional mood scale.
Review : PPARγ Agonist Beyond Glucose Lowering Effect
( Akira Sugawara ),( Akira Uruno ),( Masataka Kudo ),( Ken Matsuda ),( Chul Woo Yang ),( Sadayoshi Ito ) 대한내과학회 2011 The Korean Journal of Internal Medicine Vol.26 No.1
The nuclear hormone receptor PPARγ is activated by several agonists, including members of the thiazolidinedione group of insulin sensitizers. Pleiotropic beneficial effects of these agonists, independent of their blood glucose- lowering effects, have recently been demonstrated in the vasculature. PPARγ agonists have been shown to lower blood pressure in animals and humans, perhaps by suppressing the renin-angiotensin (Ang)-aldosterone system (RAAS), including the inhibition of Ang II type 1 receptor expression, Ang-II-mediated signaling pathways, and Ang-II-induced adrenal aldosterone synthesis/secretion. PPARγ agonists also inhibit the progression of atherosclerosis in animals and humans, possibly through a pathway involving the suppression of RAAS and the thromboxane A2 system, as well as the protection of endothelial function. Moreover, PPARγ-agonist-mediated renal protection, especially the reduction of albuminuria, has been observed in diabetic nephropathy, including animal models of the disease, and in non-diabetic renal dysfunction. The renal protective activities may reflect, at least in part, the ability of PPARγ agonists to lower blood pressure, protect endothelial function, and cause vasodilation of the glomerular efferent arterioles. Additionally, anti-neoplastic effects of PPARγ agonists have recently been described. Based on the multiple therapeutic actions of PPARγ agonists, they will no doubt lead to novel approaches in the treatment of lifestyle-related and other diseases. (Korean J Intern Med 2011;26:19-24)